Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (7109)
All Articles published online
|
Dec 28, 2008 (publication date) through Nov 3, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: |
Ford AC, Malfertheiner P, Giguère M, Santana J, Khan M, Moayyedi P. Adverse events with bismuth salts for |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v14/i48/7361.htm |
| Number | Citing Articles |
| 1 |
Gijsbert B. van der Voet. Side Effects of Drugs Annual 32 - A worldwide yearly survey of new data and trends in adverse drug reactions and interactions. Side Effects of Drugs Annual 2010; 32: 413 doi: 10.1016/S0378-6080(10)32022-8
|
| 2 |
Min Gong, Rui Zhang, Jianyan Qi, Jue Wang, Qian Liu, Hongyan Zhou, Yumeng Song, Xiaomeng Song, Yufeng Mei. In vitro evaluation of the antibacterial effect of colloidal bismuth subcitrate on Porphyromonas gingivalis and its biofilm. Archives of Oral Biology 2022; 133: 105300 doi: 10.1016/j.archoralbio.2021.105300
|
| 3 |
Ji-jun Fu, Jun-jie Guo, Ai-ping Qin, Xi-yong Yu, Qiang Zhang, Xue-ping Lei, Yu-gang Huang, Ming-yue Chen, Jie-xia Li, Yu Zhang, Jing-ping Liu, Yuan-ye Dang, Dan Wu, Xiao-ya Zhao, Zhong-xiao Lin, Yin-lei Lin, Song-pei Li, Ling-yan Zhang. Bismuth chelate as a contrast agent for X-ray computed tomography. Journal of Nanobiotechnology 2020; 18(1) doi: 10.1186/s12951-020-00669-4
|
| 4 |
Wen Zhong Liu, Yong Xie, Hong Cheng, Nong Hua Lu, Fu Lian Hu, Wan Dai Zhang, Li Ya Zhou, Ye Chen, Zhi Rong Zeng, Chong Wen Wang, Shu Dong Xiao, Guo Zong Pan, Pin Jin Hu. Fourth Chinese National Consensus Report on the management of Helicobacter pylori infection. Journal of Digestive Diseases 2013; 14(5): 211 doi: 10.1111/1751-2980.12034
|
| 5 |
Ning Song, Wen Zheng, Bin Song, Jie Zheng. Allosteric Regulation and Inhibition of Coronavirus 3CLpro Revealed by HDX‐MS. ChemBioChem 2024; 25(13) doi: 10.1002/cbic.202400001
|
| 6 |
Vincenzo De Francesco, Enzo Ierardi, Cesare Hassan, Angelo Zullo. Is Furazolidone Therapy for Helicobacter pylori Effective and Safe?. Digestive Diseases and Sciences 2009; 54(10): 2298 doi: 10.1007/s10620-009-0748-x
|
| 7 |
Jun-Hyung Cho.
Bismuth add-on improves the efficacy of 2-week tegoprazan-based triple therapy for first-line
Helicobacter pylori
eradication: a real-world evidence study
. Expert Review of Anti-infective Therapy 2024; : 1 doi: 10.1080/14787210.2024.2329251
|
| 8 |
P Malfertheiner, F Megraud, C A O'Morain, J P Gisbert, E J Kuipers, A T Axon, F Bazzoli, A Gasbarrini, J Atherton, D Y Graham, R Hunt, P Moayyedi, T Rokkas, M Rugge, M Selgrad, S Suerbaum, K Sugano, E M El-Omar. Management ofHelicobacter pyloriinfection—the Maastricht V/Florence Consensus Report. Gut 2017; 66(1): 6 doi: 10.1136/gutjnl-2016-312288
|
| 9 |
Ki Young Huh, Hyewon Chung, Yu Kyong Kim, SeungHwan Lee, Siddharth Bhatia, Yohei Takanami, Ryou Nakaya, Kyung‐Sang Yu. Evaluation of safety and pharmacokinetics of bismuth‐containing quadruple therapy with either vonoprazan or lansoprazole for Helicobacter pylori eradication. British Journal of Clinical Pharmacology 2022; 88(1): 138 doi: 10.1111/bcp.14934
|
| 10 |
Jia Miao, Chao Hu, Jie Tang, Wenyan Wang, Ying Wang, Ruoting Men, Li Yang, Liqun Gu, Naoki Yoshida, Richard Czerniak. Pharmacokinetics, Safety, and Tolerability of Vonoprazan‐ or Esomeprazole‐Based Bismuth‐Containing Quadruple Therapy: A Phase 1, Double‐Blind, Parallel‐Group Study in Adults with Helicobacter pylori Infection in China. Clinical Pharmacology in Drug Development 2023; 12(10): 1036 doi: 10.1002/cpdd.1276
|
| 11 |
Da Wit Shin, Dae Young Cheung, Ji Hee Song, Kyungseok Choi, Jihye Lim, Han Hee Lee, Jin Il Kim, Soo-Heon Park. The benefit of the bismuth add-on to the 2-week clarithromycin-based triple regimen for Helicobacter pylori eradication: a propensity score-matched retrospective study. Gut Pathogens 2023; 15(1) doi: 10.1186/s13099-023-00539-y
|
| 12 |
Niandi Tan, Hao Wu, Cheng Lan, Chengxia Liu, Aijun Liao, Zhiyong Jiao, Dongxing Su, Xiaomei Zhang, Zhe Zhang, Weiming Xiao, Fangfang Li, Xing Li, Min Xia, Rongyuan Qiu, Huixin Chen, Youli Liu, Mei Su, Minhu Chen, Yinglian Xiao. The efficacy of keverprazan-based quadruple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind, multicentre trial. International Journal of Antimicrobial Agents 2024; 64(5): 107320 doi: 10.1016/j.ijantimicag.2024.107320
|
| 13 |
Wen-xin Jiang, Jun-Ru Qi, Jin-song Liao, Zhi-li Wan, Wan-ling Liang, Jia-yi Huang, Yong Cao, Jie Xiao, Xiao-Quan Yang. Structural characterization of pectin-bismuth complexes and their aggregation in acidic conditions. International Journal of Biological Macromolecules 2020; 154: 788 doi: 10.1016/j.ijbiomac.2020.03.143
|
| 14 |
Chanagune Srinarong, Sith Siramolpiwat, Arti Wongcha-um, Varocha Mahachai, Ratha-Korn Vilaichone. Improved Eradication Rate of Standard Triple Therapy by Adding Bismuth and Probiotic Supplement for Helicobacter pylori Treatment in Thailand. Asian Pacific Journal of Cancer Prevention 2014; 15(22): 9909 doi: 10.7314/APJCP.2014.15.22.9909
|
| 15 |
Jeana Hong, Hye Ran Yang. Efficacy of Proton Pump Inhibitor-based Triple Therapy and Bismuth-based Quadruple Therapy forHelicobacter pyloriEradication in Korean Children. Pediatric Gastroenterology, Hepatology & Nutrition 2012; 15(4): 237 doi: 10.5223/pghn.2012.15.4.237
|
| 16 |
Olga P Nyssen, Dmitry Bordin, Bojan Tepes, Ángeles Pérez-Aisa, Dino Vaira, Maria Caldas, Luis Bujanda, Manuel Castro-Fernandez, Frode Lerang, Marcis Leja, Luís Rodrigo, Theodore Rokkas, Limas Kupcinskas, Jorge Pérez-Lasala, Laimas Jonaitis, Oleg Shvets, Antonio Gasbarrini, Halis Simsek, Anthony T R Axon, György Buzás, Jose Carlos Machado, Yaron Niv, Lyudmila Boyanova, Adrian Goldis, Vincent Lamy, Ante Tonkic, Krzysztof Przytulski, Christoph Beglinger, Marino Venerito, Peter Bytzer, Lisette Capelle, Tomica Milosavljević, Vladimir Milivojevic, Lea Veijola, Javier Molina-Infante, Liudmila Vologzhanina, Galina Fadeenko, Ines Ariño, Giulia Fiorini, Ana Garre, Jesús Garrido, Cristina F Pérez, Ignasi Puig, Frederic Heluwaert, Francis Megraud, Colm O'Morain, Javier P Gisbert. European Registry on Helicobacter pylori management (Hp-EuReg): patterns and trends in first-line empirical eradication prescription and outcomes of 5 years and 21 533 patients. Gut 2021; 70(1): 40 doi: 10.1136/gutjnl-2020-321372
|
| 17 |
Francisco Buitrago Ramírez, Eloísa Rodríguez Torres, Javier Alejandre Carmona. Criterios actuales para la erradicación de Helicobacter pylori. FMC - Formación Médica Continuada en Atención Primaria 2010; 17(3): 158 doi: 10.1016/S1134-2072(10)70063-3
|
| 18 |
Rachid Hajji, Sawssen Hajji, Ali Ben Ahmed, Moncef Nasri, Faouzi Hlel. Synthesis, physical characterization, thermal studies, biological activities and DFT computations on the molecular structure and vibrational spectra of [C7H12N2]2Bi2Br10·4H2O compound. Journal of Solid State Chemistry 2020; 288: 121402 doi: 10.1016/j.jssc.2020.121402
|
| 19 |
Xiao Liang, Xiaoqing Xu, Qing Zheng, Wei Zhang, Qinjuan Sun, Wenzhong Liu, Shudong Xiao, Hong Lu. Efficacy of Bismuth-Containing Quadruple Therapies for Clarithromycin-, Metronidazole-, and Fluoroquinolone-Resistant Helicobacter pylori Infections in a Prospective Study. Clinical Gastroenterology and Hepatology 2013; 11(7): 802 doi: 10.1016/j.cgh.2013.01.008
|
| 20 |
Yi Hu, Yin Zhu, Nong-Hua Lu. Novel and Effective Therapeutic Regimens for Helicobacter pylori in an Era of Increasing Antibiotic Resistance. Frontiers in Cellular and Infection Microbiology 2017; 7 doi: 10.3389/fcimb.2017.00168
|
| 21 |
Yaping Cao, Jian Zhang, Yuan Liu, Lifeng Zhang, Lu Wang, Jie Wang, Ying Qi, Huanhuan Lv, Juan Liu, Lijuan Huo, Xiaoguo Wei, Yongquan Shi. The efficacy and safety of different bismuth agents in Helicobacter pylori first-line eradication. Medicine 2021; 100(50): e27923 doi: 10.1097/MD.0000000000027923
|
| 22 |
Ben Wang, You‐Hua Wang, Zhi‐Fa Lv, Hui‐Fang Xiong, Hui Wang, Yang Yang, Yong Xie. Review: Efficacy and Safety of Hybrid Therapy for Helicobacter pylori Infection: A Systematic Review and Meta‐analysis. Helicobacter 2015; 20(2): 79 doi: 10.1111/hel.12180
|
| 23 |
J. P. Gisbert, M. Romano, A. G. Gravina, P. Solís‐Muñoz, F. Bermejo, J. Molina‐Infante, M. Castro‐Fernández, J. Ortuño, A. J. Lucendo, M. Herranz, I. Modolell, F. del Castillo, J. Gómez, J. Barrio, B. Velayos, B. Gómez, J. L. Domínguez, A. Miranda, M. Martorano, A. Algaba, M. Pabón, T. Angueira, L. Fernández‐Salazar, A. Federico, A. C. Marín, A. G. McNicholl. Helicobacter pylori second‐line rescue therapy with levofloxacin‐ and bismuth‐containing quadruple therapy, after failure of standard triple or non‐bismuth quadruple treatments. Alimentary Pharmacology & Therapeutics 2015; 41(8): 768 doi: 10.1111/apt.13128
|
| 24 |
Qinjuan Sun, Xiao Liang, Qing Zheng, Wenzhong Liu, Shudong Xiao, Weiqi Gu, Hong Lu. High Efficacy of 14‐Day Triple Therapy‐Based, Bismuth‐Containing Quadruple Therapy for Initial Helicobacter pylori Eradication. Helicobacter 2010; 15(3): 233 doi: 10.1111/j.1523-5378.2010.00758.x
|
| 25 |
Aamir Saleem, Asghar Qasim, Humphrey J O’Connor, Colm A O’Morain. Pylera®for the eradication ofHelicobacter pyloriinfection. Expert Review of Anti-infective Therapy 2009; 7(7): 793 doi: 10.1586/eri.09.55
|
| 26 |
S. V. Turkina, M. E. Statsenko, I. A. Tyshchenko. Syndrome of increased epithelial permeability: opportunities of current pharmacotherapy. Experimental and Clinical Gastroenterology 2023; (8): 123 doi: 10.31146/1682-8658-ecg-204-8-123-132
|
| 27 |
Paul T. Reynolds, Kathleen C. Abalos, Jennifer Hopp, Mark E. Williams. Bismuth Toxicity: A Rare Cause of Neurologic Dysfunction. International Journal of Clinical Medicine 2012; 3(01): 46 doi: 10.4236/ijcm.2012.31010
|
| 28 |
Vasilios Papastergiou, Sotirios D Georgopoulos, Stylianos Karatapanis. Treatment of <italic>Helicobacter pylori</italic> infection: Meeting the challenge of antimicrobial resistance. World Journal of Gastroenterology 2014; 20(29): 9898-9911 doi: 10.3748/wjg.v20.i29.9898
|
| 29 |
Ying Zhou, Ziqing Ye, Yuhuan Wang, Ye Zhang, Zifei Tang, Weili Yan, Yuan Jiang, Ying Huang. Comparison of four different regimens against Helicobacter pylori as a first‐line treatment: A prospective, cross‐sectional, comparative, open trial in Chinese children. Helicobacter 2020; 25(2) doi: 10.1111/hel.12679
|
| 30 |
Gamal M. El-Sherbiny, Mahmoud K. M. Elbestawy. A review – plant essential oils active againstHelicobacter pylori. Journal of Essential Oil Research 2022; 34(3): 203 doi: 10.1080/10412905.2022.2025464
|
| 31 |
Kallirroi Kotilea, Samy Cadranel, Assaad Salame, Julie Nguyen, Tania Mahler, Véronique Yvette Miendje Deyi, Laurine Verset, Patrick Bontems. Efficacy and safety of bismuth‐based quadruple therapy forHelicobacterpylorieradication in children. Helicobacter 2021; 26(4) doi: 10.1111/hel.12825
|
| 32 |
Amir Hossein Miri, Mojtaba Kamankesh, Mazda Rad-Malekshahi, Abbas Yadegar, Maryam Banar, Michael R. Hamblin, Ismaeil Haririan, Hamid Asadzadeh Aghdaei, Mohammad Reza Zali. Factors associated with treatment failure, and possible applications of probiotic bacteria in the arsenal againstHelicobacter pylori. Expert Review of Anti-infective Therapy 2023; 21(6): 617 doi: 10.1080/14787210.2023.2203382
|
| 33 |
Olga P. Nyssen, Angeles Perez-Aisa, Bojan Tepes, Manuel Castro-Fernandez, Juozas Kupcinskas, Laimas Jonaitis, Luis Bujanda, Alfredo Lucendo, Natasa Brglez Jurecic, Jorge Perez-Lasala, Oleg Shvets, Galina Fadeenko, Jose M. Huguet, Zdenki Kikec, Dmitry Bordin, Irina Voynovan, Marcis Leja, Jose Carlos Machado, Miguel Areia, Luis Fernandez-Salazar, Luis Rodrigo, Sergey Alekseenko, Jesus Barrio, Juan Ortuño, Monica Perona, Liudmila Vologzhanina, Pilar Mata Romero, Oleg Zaytsev, Theodore Rokkas, Sotirios Georgopoulos, Rinaldo Pellicano, Gyorgy M. Buzas, Ines Modolell, Blas Jose Gomez Rodriguez, Ilkay Simsek, Cem Simsek, Marina Roldan Lafuente, Tatiana Ilchishina, Judith Gomez Camarero, Manuel Dominguez-Cajal, Vassiliki Ntouli, Natalia Nikolaevna Dekhnich, Perminder Phull, Oscar Nuñez, Frode Lerang, Marino Venerito, Frederic Heluwaert, Ante Tonkic, Maria Caldas, Ignasi Puig, Francis Megraud, Colm O'Morain, Javier P. Gisbert. Adverse Event Profile During the Treatment of Helicobacter pylori: A Real-World Experience of 22,000 Patients From the European Registry on H. pylori Management (Hp-EuReg). American Journal of Gastroenterology 2021; 116(6): 1220 doi: 10.14309/ajg.0000000000001246
|
| 34 |
Sung Woo Ko, Yeon‐Ji Kim, Woo Chul Chung, Seung Jae Lee. Bismuth supplements as the first‐line regimen for Helicobacter pylori eradication therapy: Systemic review and meta‐analysis. Helicobacter 2019; 24(2) doi: 10.1111/hel.12565
|
| 35 |
Su Golder, Yoon K. Loke. The performance of adverse effects search filters in MEDLINE and EMBASE. Health Information & Libraries Journal 2012; 29(2): 141 doi: 10.1111/j.1471-1842.2012.00980.x
|
| 36 |
Ersin Kılınç, Sezgin Bakırdere, Fırat Aydın, O. Yavuz Ataman. Sensitive determination of bismuth by flame atomic absorption spectrometry using atom trapping in a slotted quartz tube and revolatilization with organic solvent pulse. Spectrochimica Acta Part B: Atomic Spectroscopy 2012; 73: 84 doi: 10.1016/j.sab.2012.06.004
|
| 37 |
Wouter J den Hollander, Ernst J Kuipers. Current pharmacotherapy options for gastritis. Expert Opinion on Pharmacotherapy 2012; 13(18): 2625 doi: 10.1517/14656566.2012.747510
|
| 38 |
Francis Mégraud. The challenge of Helicobacter pylori resistance to antibiotics: the comeback of bismuth-based quadruple therapy. Therapeutic Advances in Gastroenterology 2012; 5(2): 103 doi: 10.1177/1756283X11432492
|
| 39 |
Antonio Francesco Ciccaglione, Roberta Tavani, Laurino Grossi, Luigina Cellini, Lamberto Manzoli, Leonardo Marzio. Rifabutin Containing Triple Therapy and Rifabutin with Bismuth Containing Quadruple Therapy for Third‐Line Treatment of Helicobacter pylori Infection: Two Pilot Studies. Helicobacter 2016; 21(5): 375 doi: 10.1111/hel.12296
|
| 40 |
Yuhong Yuan, Alex C Ford, Khurram J Khan, Javier P Gisbert, David Forman, Grigorios I Leontiadis, Frances Tse, Xavier Calvet, Carlo Fallone, Lori Fischbach, Giuseppina Oderda, Franco Bazzoli, Paul Moayyedi. Optimum duration of regimens forHelicobacter pylorieradication. Cochrane Database of Systematic Reviews 2013; doi: 10.1002/14651858.CD008337.pub2
|
| 41 |
Zhiqiang Song, Liya Zhou, Jianzhong Zhang, Lihua He, Peng Bai, Yan Xue. Levofloxacin, bismuth, amoxicillin and esomeprazole as second-line Helicobacter pylori therapy after failure of non-bismuth quadruple therapy. Digestive and Liver Disease 2016; 48(5): 506 doi: 10.1016/j.dld.2016.01.002
|
| 42 |
Guang-Hong Jheng, I-Chen Wu, Hsiang-Yao Shih, Meng-Chieh Wu, Fu-Chen Kuo, Huang-Ming Hu, Chung-Jung Liu, Wen-Hung Hsu, Chi-Tan Hu, Ming-Jong Bair, Chao-Hung Kuo, Deng-Chyang Wu, Ping-I Hsu. Comparison of Second-Line Quadruple Therapies with or without Bismuth forHelicobacter pyloriInfection. BioMed Research International 2015; 2015: 1 doi: 10.1155/2015/163960
|
| 43 |
David Y. Graham, Sun-Young Lee. How to Effectively Use Bismuth Quadruple Therapy. Gastroenterology Clinics of North America 2015; 44(3): 537 doi: 10.1016/j.gtc.2015.05.003
|
| 44 |
Chuan Xie, Nong‐Hua Lu. Review: Clinical Management of Helicobacter pylori Infection in China. Helicobacter 2015; 20(1): 1 doi: 10.1111/hel.12178
|
| 45 |
Antonio Francesco Ciccaglione, Luigina Cellini, Leonardo Marzio. Pylera® plus ranitidine vs Pylera® plus esomeprazole in first‐line treatment of Helicobacter pylori infection: Two pilot studies. Helicobacter 2019; 24(5) doi: 10.1111/hel.12606
|
| 46 |
Xiao-Min Liao, Gao-Hui Nong, Mei-Zu Chen, Xue-Ping Huang, Yun-Yan Cong, Yi-Ying Huang, Bai-He Wu, Jin-Qi Wei. Modified sequential therapy <italic>vs</italic> quadruple therapy as initial therapy in patients with <italic>Helicobacter</italic> infection. World Journal of Gastroenterology 2015; 21(20): 6310-6316 doi: 10.3748/wjg.v21.i20.6310
|
| 47 |
Sun‐Young Lee, Jeong Hwan Kim, In‐Kyung Sung, Hyung Seok Park. Twice‐daily intake of bismuth‐based quadruple therapy for first‐line Helicobacter pylori eradication: A retrospective study on 10‐day, 14‐day, and half‐dose antibiotic therapy. Helicobacter 2023; 28(4) doi: 10.1111/hel.12998
|
| 48 |
Bruce A. Fowler, Dexter W. Sullivan, Mary J. Sexton. Handbook on the Toxicology of Metals. 2015; : 655 doi: 10.1016/B978-0-444-59453-2.00031-7
|
| 49 |
Yiqiao Xin, Jan Manson, Lindsay Govan, Robin Harbour, Jenny Bennison, Eleanor Watson, Olivia Wu. Pharmacological regimens for eradication of Helicobacter pylori: an overview of systematic reviews and network meta-analysis. BMC Gastroenterology 2016; 16(1) doi: 10.1186/s12876-016-0491-7
|
| 50 |
Gil Ho Lee, Kee Myung Lee, Sung Jae Shin, Joon Koo Kang, Choong-Kyun Noh, Jin Hong Kim, Sun Gyo Lim. Impact of previous metronidazole exposure on metronidazole-based second-line quadruple therapy for Helicobacter pylori infection . The Korean Journal of Internal Medicine 2020; 35(5): 1094 doi: 10.3904/kjim.2020.174
|
| 51 |
Peter Malfertheiner. Helicobacter pylori eradication – Author's reply. The Lancet 2011; 378(9788): 314 doi: 10.1016/S0140-6736(11)61161-6
|
| 52 |
Hang Gong, Hui-Mei Xu, De-Kui Zhang. Focusing on Helicobacter pylori infection in the elderly. Frontiers in Cellular and Infection Microbiology 2023; 13 doi: 10.3389/fcimb.2023.1121947
|
| 53 |
Vladimir I. Simanenkov, Igor V. Maev, Olga N. Tkacheva, Sergei A. Alekseenko, Dmitry Andreev, Natalia V. Bakulina, Igor G. Bakulin, Dmitry S. Bordin, Timur D. Vlasov, Natalya M. Vorobyeva, Vladimir B. Grinevich, Irina V. Gubonina, Michail Y. Drobizhev, Nikolay S. Efremov, Andrey E. Karateev, Yulia V. Kotovskaya, Iurii Kravchuk, Grigory G. Krivoborodov, Ekaterina V. Kulchavenya, Aleksander M. Lila, Marina V. Maevskaya, Anna S. Nekrasova, Elena A. Poluektova, Tatiana V. Popkova, Oleg A. Sablin, Olga I. Solovyeva, Alexander N. Suvorov, Galina N. Tarasova, Dmity I. Trukhan, Anastasia V. Fedotova. Epithelial protective therapy in comorbid diseases. Practical Guidelines for Physicians. Terapevticheskii arkhiv 2022; 94(8): 940 doi: 10.26442/00403660.2022.08.201523
|
| 54 |
Vaneet Jearth, Ashutosh Ishan Yadav, Jimil Shah, Anupam Kumar Singh, Sridhar Sundaram, Vishal Sharma, Usha Dutta, Govind Makharia, Manas Kumar Panigrahi. A survey of practice patterns and adherence to national and international guidelines on the management of Helicobacter pylori infection among gastroenterologists and gastroenterology fellows in India. Indian Journal of Gastroenterology 2024; doi: 10.1007/s12664-024-01694-z
|
| 55 |
J. C. Delchier, P. Malfertheiner, R. Thieroff‐Ekerdt. Use of a combination formulation of bismuth, metronidazole and tetracycline with omeprazole as a rescue therapy for eradication of Helicobacter pylori. Alimentary Pharmacology & Therapeutics 2014; 40(2): 171 doi: 10.1111/apt.12808
|
| 56 |
Anthony O'Connor, Javier Gisbert, Colm O’Morain. Treatment of Helicobacter pylori Infection. Helicobacter 2009; 14(s1): 46 doi: 10.1111/j.1523-5378.2009.00704.x
|
| 57 |
Anthony O’Connor, Javier P. Gisbert, Deirdre McNamara, Colm O’Morain. Treatment of Helicobacter pylori Infection 2010. Helicobacter 2010; 15(s1): 46 doi: 10.1111/j.1523-5378.2010.00774.x
|
| 58 |
Peter Malfertheiner, Francis Megraud, Theodore Rokkas, Javier P Gisbert, Jyh-Ming Liou, Christian Schulz, Antonio Gasbarrini, Richard H Hunt, Marcis Leja, Colm O'Morain, Massimo Rugge, Sebastian Suerbaum, Herbert Tilg, Kentaro Sugano, Emad M El-Omar. Management ofHelicobacter pyloriinfection: the Maastricht VI/Florence consensus report. Gut 2022; 71(9): 1724 doi: 10.1136/gutjnl-2022-327745
|
| 59 |
Ivana Marzano, Marina Franco, Priscila Silva, Rodinei Augusti, Geandson Santos, Nelson Fernandes, Mônica Bucciarelli-Rodriguez, Edmar Chartone-Souza, Elene Pereira-Maia. Crystal Structure, Antibacterial and Cytotoxic Activities of a New Complex of Bismuth(III) with Sulfapyridine. Molecules 2013; 18(2): 1464 doi: 10.3390/molecules18021464
|
| 60 |
Annu Aggarwal, Mohit Bhatt. Neurologic Aspects of Systemic Disease Part II. Handbook of Clinical Neurology 2014; 120: 633 doi: 10.1016/B978-0-7020-4087-0.00043-7
|
| 61 |
Bilal Ergül, Zeynal Doğan,, Murat Sarikaya, Levent Filik. The Efficacy of Two‐Week Quadruple First‐Line Therapy with Bismuth, Lansoprazole, Amoxicillin, Clarithromycin on Helicobacter pylori Eradication: A Prospective Study. Helicobacter 2013; 18(6): 454 doi: 10.1111/hel.12086
|
| 62 |
Runming Wang, Jasper Fuk-Woo Chan, Suyu Wang, Hongyan Li, Jiajia Zhao, Tiffany Ka-Yan Ip, Zhong Zuo, Kwok-Yung Yuen, Shuofeng Yuan, Hongzhe Sun. Orally administered bismuth drug together with N-acetyl cysteine as a broad-spectrum anti-coronavirus cocktail therapy. Chemical Science 2022; 13(8): 2238 doi: 10.1039/D1SC04515F
|
| 63 |
Peter Malfertheiner, Franco Bazzoli, Jean-Charles Delchier, Krysztof Celiñski, Monique Giguère, Marc Rivière, Francis Mégraud. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial. The Lancet 2011; 377(9769): 905 doi: 10.1016/S0140-6736(11)60020-2
|
| 64 |
Youhua Wang, Ben Wang, Zhi Fa Lv, Yang Yang, Fucai Wang, Hui Wang, Shuping Chen, Yong Xie, Xiaojiang Zhou. Efficacy and Safety of Ecabet Sodium as an Adjuvant Therapy for Helicobacter pylori Eradication: A Systematic Review and Meta‐Analysis. Helicobacter 2014; 19(5): 372 doi: 10.1111/hel.12136
|
| 65 |
Shasha Chen, Weina Shen, Yuhuan Liu, Qiang Dong, Yongquan Shi. Efficacy and safety of triple therapy containing berberine, amoxicillin, and vonoprazan for Helicobacter pylori initial treatment: A randomized controlled trial. Chinese Medical Journal 2023; 136(14): 1690 doi: 10.1097/CM9.0000000000002696
|
| 66 |
Hale Gokcan, Erkin Oztas, Ibrahim Koral Onal. Different bismuth-based therapies for eradicating Helicobacter pylori: Randomized clinical trial of efficacy and safety. Clinics and Research in Hepatology and Gastroenterology 2016; 40(1): 124 doi: 10.1016/j.clinre.2015.06.014
|
| 67 |
Seiichiro Himeno, Hitomi Fujishiro, Daigo Sumi. Handbook on the Toxicology of Metals. 2022; : 121 doi: 10.1016/B978-0-12-822946-0.00005-2
|
| 68 |
Marfa N. Egorikhina, Andrey E. Bokov, Irina N. Charykova, Yulia P. Rubtsova, Daria D. Linkova, Irina I. Kobyakova, Ekaterina A. Farafontova, Svetlana Ya. Kalinina, Yuri N. Kolmogorov, Diana Ya. Aleynik. Biological Characteristics of Polyurethane-Based Bone-Replacement Materials. Polymers 2023; 15(4): 831 doi: 10.3390/polym15040831
|
| 69 |
Hatainuch Prapitpaiboon, Varocha Mahachai, Ratha-Korn Vilaichone. High Efficacy of Levofloxacin-Dexlansoprazole-Based Quadruple Therapy as a First Line Treatment for Helicobacter pylori Eradication in Thailand. Asian Pacific Journal of Cancer Prevention 2015; 16(10): 4353 doi: 10.7314/APJCP.2015.16.10.4353
|
| 70 |
Muhammet Yener Akpinar, Evrim Kahramanoglu Aksoy, Ferdane Sapmaz, Zeynep Goktas, Metin Uzman, Yasar Nazligul. Comparison of moxifloxacin-based therapies and standard bismuth-based quadruple therapy for first-line treatment of Helicobacter pylori infection. Archives of Medical Science – Civilization Diseases 2018; 3(1): 81 doi: 10.5114/amscd.2018.78766
|
| 71 |
Dahiana M. Díaz-Rodríguez, Javier A. Bustamante-Rengifo, Herney A. García-Perdomo. Efficacy and Safety of Standard Triple Therapy for Helicobacter pylori Eradication in Latin America. Journal of Clinical Gastroenterology 2024; doi: 10.1097/MCG.0000000000002064
|
| 72 |
Stephan Miehlke, Dorothea Frederking, Thomas Günther, Erik Glocker, Bianca Eisele, Viola Andresen, Sören Schröder, Andrea Morgner. Efficacy of three‐in‐one capsule bismuth quadruple therapy for Helicobacter pylori eradication in clinical practice in a multinational patient population. Helicobacter 2017; 22(6) doi: 10.1111/hel.12429
|
| 73 |
Kichul Yoon, Nayoung Kim, Jung Won Lee, Hyuk Yoon, Cheol Min Shin, Young Soo Park, Dong Ho Lee. Annual eradication rate of bismuth‐containing quadruple therapy as second‐line treatment forHelicobacter pyloriinfection: A 15‐year prospective study at a tertiary hospital in Korea. Helicobacter 2020; 25(3) doi: 10.1111/hel.12685
|
| 74 |
Daniel Pohl, Peter M Keller, Valentine Bordier, Karoline Wagner. Review of current diagnostic methods and advances in <i>Helicobacter pylori</i> diagnostics in the era of next generation sequencing. World Journal of Gastroenterology 2019; 25(32): 4629-4660 doi: 10.3748/wjg.v25.i32.4629
|
| 75 |
|
| 76 |
Mārcis Leja, Uga Dumpis. What Would the Screen-and-Treat Strategy for Helicobacter pylori Mean in Terms of Antibiotic Consumption?. Digestive Diseases and Sciences 2020; 65(6): 1632 doi: 10.1007/s10620-019-05893-z
|
| 77 |
Ji Yeon Kim, Sun‐Young Lee, Jeong Hwan Kim, In‐Kyung Sung, Hyung Seok Park. Efficacy and safety of twice a day, bismuth‐containing quadruple therapy using high‐dose tetracycline and metronidazole for second‐line Helicobacter pylori eradication. Helicobacter 2020; 25(2) doi: 10.1111/hel.12683
|
| 78 |
Peter Malfertheiner, M. Constanza Camargo, Emad El-Omar, Jyh-Ming Liou, Richard Peek, Christian Schulz, Stella I. Smith, Sebastian Suerbaum. Helicobacter pylori infection. Nature Reviews Disease Primers 2023; 9(1) doi: 10.1038/s41572-023-00431-8
|
| 79 |
Javier P. Gisbert, Adrian G. McNicholl. Optimization strategies aimed to increase the efficacy of H. pylori eradication therapies. Helicobacter 2017; 22(4) doi: 10.1111/hel.12392
|
| 80 |
Olga Sjomina, Alise Lielause, Aiga Rūdule, Reinis Vangravs, Sergejs Paršutins, Inese Poļaka, Ilva Daugule, Ilmārs Stonāns, Jin Young Park, Mārcis Leja. Randomised clinical trial: comparison of efficacy and adverse effects of a standard triple clarithromycin-containing regimen with high-dose amoxicillin and bismuth therapy in Helicobacter pylori eradication. European Journal of Cancer Prevention 2022; 31(4): 333 doi: 10.1097/CEJ.0000000000000718
|
| 81 |
Hidekazu Suzuki, Juntaro Matsuzaki, Toshifumi Hibi. Metronidazole-based quadruple versus standard triple therapy: which is better as first-line therapy forHelicobacter pylorieradication?. Expert Review of Clinical Pharmacology 2011; 4(5): 579 doi: 10.1586/ecp.11.34
|
| 82 |
Emma L. Hawksworth, Philip C. Andrews, Wilford Lie, Barry Lai, Carolyn T. Dillon. Biological evaluation of bismuth non-steroidal anti-inflammatory drugs (BiNSAIDs): Stability, toxicity and uptake in HCT-8 colon cancer cells. Journal of Inorganic Biochemistry 2014; 135: 28 doi: 10.1016/j.jinorgbio.2014.02.012
|
| 83 |
Peter Malfertheiner, Michael Selgrad. Helicobacter pylori infection and current clinical areas of contention. Current Opinion in Gastroenterology 2010; 26(6): 618 doi: 10.1097/MOG.0b013e32833efede
|
| 84 |
Meiying Liu, Youxiu Zhong, Jing Chen, Yu Liu, Chongfa Tang, Xuewei Wang, Yanbin Zhang, Ping Wang, Susan M. Logan, Wangxue Chen, Bo Wei. Oral immunization of mice with a multivalent therapeutic subunit vaccine protects against Helicobacter pylori infection. Vaccine 2020; 38(14): 3031 doi: 10.1016/j.vaccine.2020.02.036
|
| 85 |
Edith Lahner, Marilia Carabotti, Bruno Annibale. Treatment of <i>Helicobacter pylori</i> infection in atrophic gastritis. World Journal of Gastroenterology 2018; 24(22): 2373-2380 doi: 10.3748/wjg.v24.i22.2373
|
| 86 |
Michael Selgrad, Arne Kandulski, Peter Malfertheiner. Helicobacter pylori: diagnosis and treatment. Current Opinion in Gastroenterology 2009; 25(6): 549 doi: 10.1097/MOG.0b013e32833159f2
|
| 87 |
Young Woon Chang, Ga Young Shin, Jung-Wook Kim, Jin-Chang Moon, Eun Jee Chang, Chi Hyuk Oh, Jae-Young Jang. Cost-Effectiveness of Empirical Bismuth-Based Quadruple Therapy and Tailored Therapy After Clarithromycin Resistance Tests for Helicobacter pylori Eradication. Digestive Diseases and Sciences 2022; 67(4): 1222 doi: 10.1007/s10620-021-06938-y
|
| 88 |
Jie Liang, Jun Li, Ying Han, Jielai Xia, Yunsheng Yang, Wen Li, Shutian Zhang, Yongdong Wu, Yaozong Yuan, Zhaoshen Li, Yiqi Du, Minhu Chen, Baili Chen, Bo Jiang, Yang Bai, Qinsheng Wen, Kaichun Wu, Daiming Fan. Helicobacter pylori Eradication with Ecabet Sodium, Omeprazole, Amoxicillin, and Clarithromycin Versus Bismuth, Omeprazole, Amoxicillin, and Clarithromycin Quadruple Therapy: A Randomized, Open‐Label, Phase IV Trial. Helicobacter 2012; 17(6): 458 doi: 10.1111/j.1523-5378.2012.00971.x
|
| 89 |
Kiwon Shin, Min-Jae Cho, Jung-Hwan Oh, Chul-Hyun Lim. Second-Line Bismuth-Containing Quadruple Therapy for Helicobacterpylori Infection: A 12-Year Study of Annual Eradication Rates. Journal of Clinical Medicine 2021; 10(15): 3273 doi: 10.3390/jcm10153273
|
| 90 |
Wen Zhong Liu, Yong Xie, Hong Lu, Hong Cheng, Zhi Rong Zeng, Li Ya Zhou, Ye Chen, Jiang Bin Wang, Yi Qi Du, Nong Hua Lu. Fifth Chinese National Consensus Report on the management ofHelicobacter pyloriinfection. Helicobacter 2018; 23(2) doi: 10.1111/hel.12475
|
| 91 |
L. Pacifico, J. F. Osborn, C. Anania, D. Vaira, E. Olivero, C. Chiesa. Review article: bismuth‐based therapy for Helicobacter pylori eradication in children. Alimentary Pharmacology & Therapeutics 2012; 35(9): 1010 doi: 10.1111/j.1365-2036.2012.05055.x
|
| 92 |
Xiao-Dong Zhang, Da-Ya Zhang, Run-Xiang Chen, Shi-Ju Chen, Chen Chen, Fan Zeng, Shi-Mei Huang, Da Li, Fei-Hu Bai. Ilaprazole-amoxicillin dual therapy at high dose as a first-line treatment for helicobacter pylori infection in Hainan: a single-center, open-label, noninferiority, randomized controlled trial. BMC Gastroenterology 2023; 23(1) doi: 10.1186/s12876-023-02890-5
|
| 93 |
Francis Mégraud. Failed Eradication for <b><i>Helicobacter pylori</i></b>. What Should Be Done?. Digestive Diseases 2016; 34(5): 505 doi: 10.1159/000445230
|
| 94 |
Hong-Yu Luo, Shuo-Guo Xu, Li-Chen Gao, Hui-Zhi Long, Zi-Wei Zhou, Feng-Jiao Li, Shang-Ming Dai, Jin-Da Hu, Yu Su, Yan Cheng. Pharmacokinetic and Safety Study of Bismuth Potassium Citrate Formulations in Healthy Subjects. Drugs in R&D 2024; 24(1): 81 doi: 10.1007/s40268-024-00455-9
|
| 95 |
Xiaoye Shi, Chunmei Wang, Fanjun Meng, Shaoze Ma, Guangqin Xu, Tingwei Liu, Xiaozhong Guo, Hongyu Li, Xingshun Qi. Impact of insufficient doses of medications on Helicobacter pylori eradication: a retrospective observational study. Postgraduate Medicine 2022; 134(7): 668 doi: 10.1080/00325481.2022.2105094
|
| 96 |
Oguzhan Ozturk, Levent Doganay, Yasar Colak, Feruze Yilmaz Enc, Celal Ulasoglu, Kamil Ozdil, Ilyas Tuncer. Therapeutic success with bismuth-containing sequential and quadruple regimens in Helicobacter pylori eradication. Arab Journal of Gastroenterology 2017; 18(2): 62 doi: 10.1016/j.ajg.2017.05.002
|
| 97 |
Huan Li, Xiu-Juan Xia, Lin-Fang Zhang, Jing-Shu Chi, Peng Liu, Hao Wu, Xiao-Ran Xie, De-Lin Tian, Kai-Xiao Kun, Ren-jie Gong, Xiao-Ming Liu, Can-Xia Xu. Comparative study of allicin-containing quadruple therapy vs. bismuth-containing quadruple therapy for the treatment of Helicobacter pylori infection: a prospective randomized study. European Journal of Gastroenterology & Hepatology 2021; 32(2): 194 doi: 10.1097/MEG.0000000000001896
|